| Table |
|---|
Advertisement
Topics
- Industries
- BioPharmaceutical
- Medical Device
Related Companies
- Altus Pharmaceuticals Inc.
- Alexza Pharmaceuticals Inc.
- AstraZeneca PLC
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi
- Daiichi Sankyo Co. Ltd.
- Sankyo Co. Ltd.
- KAI Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- Affymax Inc.
- Allergan PLC
- Actavis Laboratories
- Actavis Group
- Sindan
- Pliva DD
- Ranbaxy Laboratories Ltd.
- Terapia SA
- Ethimed NV
- Insulet Corp.
- Boston Scientific Corp.
- Guidant Corp.
- Abbott Laboratories Inc.
- Allergan Inc.
- Angiotech Pharmaceuticals Inc.
- AMI Holdings Inc.
- Cepheid
- Fisher Scientific International Inc.
- Athena Diagnostics Inc.
- Nanogen Inc.
Related Deals
- Altus Pharmaceuticals completes $97.7mm IPO
- Alexza Pharmaceuticals nets $47mm from IPO
- AstraZeneca may buy back Merck's rights from their old JV
- Pfizer to buy Sanofi-Aventis' share of Exubera for $1.3bn
- KAI licenses cardiovascular candidate to Sankyo; deal ended
- Takeda licenses Affymax's Hematide for Japan; deal ends
- Watson buys Andrx for $1.9bn
- Actavis buys Sindan for €147.5mm
- Actavis bids $1.7bn for Pliva; withdrawn
- Ranbaxy buys top Romanian generics co. Terapia
- Ranbaxy expands European generics through Ethimed acquisition
- Insulet closes $50mm financing round
- Neuro-Hitech broadens CNS development via Q-RNA takeover
- Abbott acquires Guidant's vascular business
- Allergan pays $3.1bn for Inamed
- Angiotech Pharmaceuticals buys device company AMI Holdings
- Fisher Scientific buys Athena Diagnostics
- Fisher Scientific takes a stake in Nanogen
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IV002758
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
IV002758
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.